EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis.

Participants will be followed for up to 5.5 years.
Breast Cancer
DIAGNOSTIC_TEST: ctDNA MRD test
Core biopsy tissue evaluability rate, 3 years|Distant Recurrence Free Interval (dRFI), 6 years
Prevalence of tumor mutations and germline variants, 6 years|Sensitivity/Specificity, 6 years|Prevalence of test positivity, 6 years|Pathologic complete response (pCR) status, 6 years|Recurrence-free interval (RFI), 6 years|Invasive breast cancer-free survival (IBCFS), 6 years|Event-free survival (EFS), 6 years|Overall survival (OS), 6 years|Lead Time, 6 years
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis.

Participants will be followed for up to 5.5 years.